



## Shattuck Labs Announces Participation in the 7th Annual Truist Securities Life Sciences Summit

April 28, 2021

AUSTIN, Texas and DURHAM, N.C., April 28, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: [STTK](#)), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in the 7<sup>th</sup> Annual Truist Securities Life Sciences Summit being held virtually May 4-5, 2021.

### Presentation Details

Conference: 7<sup>th</sup> Annual Truist Securities Life Sciences Summit

Format: Fireside chat with analyst Asthika Goonewardene

Presenters: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer and Andrew Neill, Shattuck's Chief Financial Officer

Date: May 5, 2021

Time: 1:50 p.m. EST

Webcast Link: Available [Here](#)

A live webcast will be available on the [Events & Presentations](#) section of the Company's website. A replay of the webcast will be archived for up to 90 days following the presentation date.

### About Shattuck Labs, Inc.

Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC<sup>®</sup>, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company's lead wholly owned program, SL-172154 (SIRP $\alpha$ -Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN<sup>™</sup>, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: [www.ShattuckLabs.com](http://www.ShattuckLabs.com).

### Investor Contact:

Conor Richardson

Senior Director, Finance & Investor Relations

Shattuck Labs, Inc.

[InvestorRelations@shattucklabs.com](mailto:InvestorRelations@shattucklabs.com)

### Media Contact:

Stephanie Ascher

Managing Director

Stern Investor Relations, Inc.

[Stephanie.ascher@sternir.com](mailto:Stephanie.ascher@sternir.com)



Source: Shattuck Labs, Inc.